JNCCN 360 – MM – DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma

By: Melissa Steele-Ogus Posted: Friday, August 7, 2020 Belantamab mafodotin is a first-in-class maturation antigen-binding monoclonal immunoconjugate found to have clinical activity and an acceptable safety profile for treating patients with relapsed or refractory multiple…

Read the full article here

Related Articles